Skip to main content

Prevencio, Atlas Genomics to Commercialize Cardiac Blood Tests

NEW YORK — Prevencio said on Wednesday that it has signed an agreement to commercialize its artificial intelligence-based HART cardiac blood tests with Seattle-based CLIA lab Atlas Genomics.

Specific terms of the deal were not disclosed.

The tests, which use a combination of proteomic biomarkers and proprietary algorithms, include ones for obstructive coronary artery disease, the one-year risk of heart attack, stroke, or cardiac death, and Kawasaki disease.

In early 2020, Kirkland, Washington-based Prevencio inked a deal to use Microsoft's Azure AI-based computing cloud platform for test algorithm processing and scoring and for report generation and delivery. Under that agreement, Microsoft also offers the tests to its existing customer base.

"We are excited to partner with Atlas Genomics to commercially launch our HART tests for patient use on Microsoft's secure cloud," Prevencio CEO Rhonda Rhyne said in a statement. The tests "provide highly accurate results in an easy-to-understand report, allowing physicians and patients to monitor and detect changes in cardiac health conditions."